Bone marrow suppression induced by systemic radionuclides (153Sm) in metastatic breast cancer patients with bone metastases, its impact on subsequent chemotherapy
Journal Title: Współczesna Onkologia - Year 2005, Vol 9, Issue 10
Abstract
Introduction: Bone metastases are present in approximately 75 percent of breast cancer patients, therefore bones are the most frequent localization of metastases and the only site of metastatic spread in many patients. Treatment of bone metastases remains palliative. The commonly used treatment options include: radiotherapy, bisphosphonate therapy and systemic radionuclides. Purpose: The aim of this study was to assess the safety of systemic samarium (153Sm) in breast cancer patients with widespread bone metastases and the impact of bone marrow suppression induced by (153Sm) treatment on hematologic toxicity of concomitant or subsequent chemotherapy. Materials and methods: Data from ninety metastatic breast cancer patients with bone metastases treated in the Lower Silesia Oncology Centre, who in 2002-2004 received 153Sm in the Nuclear Medicine Department of the 4th Military Hospital was included in the analysis. Sixty nine (77 percent) patients had bone only disease, while in 26 (23 percent), presence of metastases to other organs was confirmed. Fifty four (60 percent) patients were treated with radiotherapy before systemic radionuclides. The majority (80/90 – 89%) of patients received concurrently bisphosphonates, all patients required analgetics. Results: The treatment with radionuclides was generally well tolerated with short-term asymptomatic bone marrow suppression. In 16 (18%) of patients (5 from the group with disease limited to bones and 11 from the group with metastatic spread to other organs) treated with 153Sm, chemotherapy was planned or initiated. In 10 (62.5%) patients chemotherapy was delayed for a mean period of 4–8 weeks, then dose intensity had to be reduced due to the prolonged reduction of bone marrow reserve. In 4 (25%) patients chemotherapy was planned but not initiated due to persistent bone marrow suppression, only 2 (12.5%) of patients received the treatment with a cytotoxic drug without delay or dose reduction. Conclusions: Results of this study indicate that in metastatic breast cancer patients, if the clinical benefit from chemotherapy is expected, a caution should be recommended in planning palliative treatment with 153Sm due to the potential delay of cytotoxic therapy, though pathogenesis of long-term bone marrow suppression is multifactorial and it is unlikely that systemic radionuclides play a key role in myelosuppression.
Authors and Affiliations
Aleksandra Łacko, Katarzyna Pająk, Andrzej Kołodziejczyk, Jacek Żebrowski, Agnieszka Garncarek, Emilia Filipczyk-Cisarż
Keywords
Related Articles
- EP ID EP112758
- DOI -
- Views 66
- Downloads 0
Epigenetic regulation of transcription factor STAT3 activity in cancer cells
The transcription factor STAT3 is increasingly viewed as an oncogene. Activated STAT3 is pro-proliferative, anti-apoptotic and oncogenic. There is growing evidence for the epigenetic regulation of STAT3 activity in can...
Radioterapia w leczeniu zaawansowanego raka jelita grubego
Użyteczność badań markerów nowotworowych w diagnostyce nowotworów głowy i szyi
Dominującym typem histologicznym wśród nowotworów głowy i szyi jest rak płaskonabłonkowy. Stwarza to określone preferencje przy doborze markerów nowotworowych, których oznaczenia są wykorzystywane w diagnostyce chorych n...
Kliniczne znaczenie wskaźnika apoptotycznego w niedrobnokomórkowym raku płuca
Apoptoza jest fizjologiczną formą śmierci komórki, podczas której eliminowane są zużyte lub uszkodzone komórki. Apoptoza nazywana jest również programowaną śmiercią komórki, ponieważ jej wystąpienie jest ściśle uwarunkow...
Diagnostyka endoskopowa raka jelita grubego
Wzrastająca zachorowalność na raka jelita grubego w populacji polskiej wymusza doskonalenie starych i poszukiwanie nowych, bardziej skutecznych metod diagnostycznych przydatnych do jego rozpoznania. Na poprawę wyników le...